Novartis' Gilenya works regardless of treatment history, says new report
This article was originally published in Scrip
Executive Summary
Novartis' Gilenya (fingolimod) reduces the risk of disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of treatment history or disease severity, according to a new analysis.